OPP001_GLP1_Companion_SaMD 📄 Overview A Class IIb SaMD (Medical Device Software) that acts as an intelligent companion for patients on GLP-1 therapy. It integrates data from EHRs, wearables (activity, sleep, smart scale body composition), and patient-reported symptoms to provide personalized guidance for side effect management (e.g., nausea, constipation), optimized nutrition plans (with emphasis on protein intake for muscle preservation), guided exercise regimens, and adherence reminders. It provides actionable insights to both patients and their clinicians, potentially suggesting dosage adjustments or intervention strategies based on real-time data. Key technologies: 👤 Target users: 👍 Benefits Improved medication adherence and persistence • Reduced severity and incidence of GLP-1 related side effects • Enhanced quality of weight loss (preserving lean muscle mass) • Better long-term patient engagement and satisfaction • Optimized clinical decision-making regarding titration and adjunctive therapies • Reduced healthcare resource utilization (e.g., fewer clinic visits for side effect management) Use bullets or new lines. 👎 Challenges Achieving SaMD regulatory clearance (Class IIb or III depending on claims) • Ensuring data interoperability across diverse systems and devices • Sustaining patient engagement over long treatment durations • Clinical validation of all claims (e.g., impact on muscle mass, specific side effect reduction) • Integration into existing clinical workflows without burdening providers 📋 Regulatory & Validation Likely Class IIb SaMD, requiring pre-market submission (e.g., 510(k) in US, CE Mark in EU) due to claims influencing treatment and patient management. • Robust cybersecurity and data privacy (HIPAA, GDPR) compliance essential. • Algorithm transparency and bias mitigation for personalization features.